Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 3/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418624 | 0.96 | KDR (0.54) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2421413 | 0.95 | KDR (0.48) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2422203 | 0.95 | KDR (0.44) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2416247 | 0.95 | KDR (0.44) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2416177 | 0.95 | MAPT (0.51) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2414657 | 0.95 | MAPT (0.51) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2412740 | 0.93 | AURKA (0.54) | KDRCDK2MMP13MAPKAPK2MAPK8 | |
| SCHEMBL2418179 | 0.93 | AURKA (0.54) | KDRCDK2MMP13MAPKAPK2MAPK8 | |
| SCHEMBL2412425 | 0.93 | KDR (0.46) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 | |
| SCHEMBL2419531 | 0.93 | KDR (0.49) | KDRCSNK2A2CSNK2BCSNK2A1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | claimed |
| US-8017643-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-7786048-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-08-31 | — | — | US | disclosed |
| US-20090233813-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | disclosed |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | CDK2, MAP3K19, MAP3K15 | KDR 1181/4885CSNK2A2 191/4885CSNK2B 155/4885 |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | CDK2, MAP3K19, MAP3K15 | KDR 1181/4885CSNK2A2 191/4885CSNK2B 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.